newsfilter
← Latest News
PR Newswire·

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory PatientsREHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene